Humans aree xposed to countless foreigncompounds,typically referred to asx enobiotics. Thesec aninclude clinically used drugs, environmentalpollutants,foodadditives,pesticides,herbicidesandevennaturalplant compounds. Xenobioticsaremetabolised primarily in the liver,b ut also int he gut andothero rgans,to derivativest hataremoree asily eliminated fromt he body. Ins omec ases,h owever,a compoundi sconverted to anelectrophilethatcancausec ell toxicity andtransformation leadingto cancer. Amongthe most important xenobiotic-metabolisinge nzymesarethe cytochromesP450( P450s). Thesee nzymesr epresent asuperfamily ofmultiplef orms that exhibitm arkedspeciesdifferencesint heirexpression andc atalytic activities. Top redicthow humans will metabolisexenobiotics,i ncluding drugs,h umanl iverextracts andrecombinant P450s haveb eenu sed.Newhumanised mousemodels areb eingd eveloped which will be ofg reatv aluei nthe studyofdrugmetabolism,pharmacokineticsandpharmacodynamics invivo,a ndi ncarryingout humanr iskassessment ofxenobiotics. Humanised mice expressingC YP2D6andC YP3A4, twom ajor drug-metabolisingP 450s,h averevealed the feasibility ofthis approach.
Introduction
CytochromesP450( P450s) andotherforeigncompound-or xenobiotic-metabolisinge nzymesarethe primary interface betweenthe chemicalenvironment andthe body. Xenobiotics include drugs,environmentalcontaminants andfoodadditives. Theycanalso encompass naturalp lant chemicals such as flavonoids,steroidsandphytoalexins. Since therea rec ountless different compoundsthatcanenteranorganism,theremust be ameans for theirelimination.Thisisp articularlyimportant for hydrophobic chemicals,which candissolvei nl ipidsand accumulatei nt he body,or thosethatcanr eactw ithc ellular macromoleculesandc ausetoxicity andc ancer. Ino rdert o copewiththe onslaughto fc hemicalinsults,mammals have evolved alarge numberofe nzymest hatappeart ofunction in the metabolism ofxenobiotics. Although somemetabolism ofe ndogenous chemicals hasbeenfound, the physiological relevance ofthesereactions isu nknown. Asag eneralp aradigm,xenobiotic-metabolisinge nzymesconvert lipid-soluble foreignchemicals into derivativesthatcaneasily be eliminated fromt he body.
Xenobiotic-metabolisinge nzymeshaveh istorically been grouped into twofunctionally distinctclasses,the phase1and phase2enzymes( Figure1). Phase1enzymesinclude the P450s,fl avin-containingmonooxygenases( FMOs) and epoxide hydrolases( EH). The phase1enzymesu seO 2 and reduced nicotinamidea denined inucleotide phosphatei n 'oxidation'reactions. The phase2enzymes,which include the glutathioneS -transferases( GSTs),uridined iphosphate-glucuronosyltransferases( UGTs), N -acetyltransferases (NATs),sulfotransferases( SULTs),methyltransferasesanda fewothers,add hydrophilic derivativestocompoundstomake themm orewaters olublea ndmoree asily eliminated fromt he body. Thesec onjugation reactions usuallyinvolveoxygen (hydroxyl or epoxide groups),nitrogenandsulphur atoms. Thus,xenobiotic-metabolisinge nzymesareresponsiblei n large part for the disposalo ff oreignchemicals fromt he body. Int he caseofc linically used drugs,xenobiotic-metabolising enzymesgenerally metabolisea ndi nactivated rugs; int he absence ofmetabolism,many drugsw ouldstayint he body andremainbiologically activef or longperiodso ftime, a propertyt hatw ould, inm ost cases,b eunfavourablea ndlead to prolonged druga ction.Ins omec ases,prodrugsarec onverted to activemetabolitesbyx enobiotic-metabolising enzymes. Alist ofxenobiotic-metabolisinge nzymesiss hown inTa ble1.
Paradoxically,the xenobiotic-metabolisingenzymesarealso responsiblef or convertingi nert chemicals to electrophilic derivativest hatcancausec ellulardamagea ndtransformation. For example, the P450s canp roduce electrophilic epoxides thatr eactw ithc ellularn ucleophiles,i ncludingD NA.Phase2 enzymescanalso participatei nactivation reactions,i np articulart hrough the production ofunstablee sters derived from N -oxidesp roduced byP450s. 8 inactivated whileothers area ctivated to electrophilic derivativesbyx enobiotic metabolism.
The ability ofxenobiotic-metabolisinge nzymest ohandle many different typesofchemicals isdueto the factthatasingle enzymec anm etabolisealarge numbero fd ifferent substrates. The substrate-bindingsitef romasingleP 450canaccommo-dated ifferent chemicals tructures. Oxidation cano ccur at different siteso nt he samemolecule.Therei salso ah igh degree ofoverlappingsubstratespecificitiesamongthese enzymes,wherebyasinglec ompoundc anbe metabolised by severalenzymes. Thus,alimited numbero fP 450s area bleto metabolisescoreso fd ifferent chemicals,a ndthiscould account for the tremendous capacity for mammals witha limited numbero fe nzymest om etabolisemany different xenobiotics.
The xenobiotic-metabolisinge nzymesarei mportant determinants for boththe favourable(diseaseor symptom amelioration induced bydruga ction)andunfavourable (toxicity andc arcinogenicity) responsest oforeignchemicals. Patientscandifferinboththeirr esponsest odrugsandtheir susceptibility to chemically-induced toxicity dueto the large degree ofi nter-individualdifferencesinl evels ofe xpression. Since thesee nzymesactivatec arcinogens,therec ouldb ea difference ins usceptibility to cancerw hich dependso nl evels ofxenobiotic-metabolisinge nzymes. Thelatterhasbeen examined bycasec ontrol epidemiologys tudiest hathave attempted to determinethe association betweencancerand the presence ofmutant allelesfor xenobiotic-metabolising enzymes.
9,10
Therea remarkedspeciesdifferencesint he expression and catalytic activitieso fxenobiotic-metabolisinge nzymes. Asa result,rodents andh umans canm etaboliseasinglec hemical entity quitedifferently.Infact,evenrats andmice,which have beenevolutionarily separated byatl east 17 million years,have uniquesets ofxenobiotic-metabolisinge nzymes. Inp articular, the xenobiotic-metabolisingP 450s show ah igh degree of speciesdifferencesinthe numberofgenes,regulation ofgenes andsubstratespecificitieso fi ndividualenzymes. 11 Inhumans, therea realimited numbero fP 450s thatarek nown to metabolisec linically used drugs,a ndthesee nzymesexhibit substratespecificitiesandregulatorypatternsthatcanmarkedly differfromP450s inm icea ndrats. Infact,c loninga nd sequencingofP 450s and, morerecently,totalgenome sequencingh averevealed 102 putatively functionalgenesand 88 pseudogenesint he mousea nd5 7p utatively functional genesand58pseudogenesinthe human.
12 Thus,humans have fewerfunctionalP450s genesthanmice,aninterestingfactthat mayhelp to develop ah ypothesiso nt he drivingf orceso fthe evolution ofxenobiotic-metabolisinge nzymes. 11 Theh uman P450s also exist inanumberofallelic forms,andinsomecases wheretherearemutant gene-inactivatingmutations,theselead to P450p olymorphisms( http://www. imm.ki.se/CYPalleles). The major P450s involved indrugmetabolism areC YP2C8, CYP2C9,C YP2C19,C YP2D6andC YP3A4.ThoseP 450s thataremainly involved int he metabolism oftoxicantsand carcinogens areC YP1A1,C YP1A2,C YP1B1,C YP2A6and CYP2E1. Themajor polymorphic P450s areC YP2A6, CYP2C9,C YP2D6andC YP2C19. OtherP450s exhibit markedi nter-individualdifferencesinl evels ofe xpression which arenot dueto polymorphisms,notably CYP3A4.
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Since drugsaremetabolised andinactivated byP450s,these enzymesdictatethe rateofd ruge limination. Inm any cases,a patient must takemorethanonemedication,andthiscanresult indruginteractions if bothagents aremetabolised bythe same P450. Thisphenomenon,referred to as'druginteractions',can lead to toxicity dueto inhibition ofmetabolism andthe resultant high andsustained serumlevels ofoneofthe drugs. Thus,i tiscriticaltodeterminewhich P450isr esponsiblef or metabolisingaparticulardrug.Infact,itisnow routinepractice for pharmaceuticalcompaniest oestablishwhich P450s metaboliseadrugb eforeitiss ubjected to clinicalt rials.
Overt he past teny ears,i thasbecomestandardpractice to determineh ow ad rugc andidatei sm etabolised andwhich P450formisr esponsiblef or its metabolism. Thisaidsint he prediction ofdrugsafety.Inparticular,byknowinghow adrug ism etabolised,i tisp ossibleto determinewhethert herewill be drugi nteractions andwhethert heremaybe problems withi nter-individualdifferencesinm etabolism andc learance caused byP450p olymorphisms. Theb est scenariofor ad rug company ist odevelop ad rugthatism etabolised bys everal forms ofP 450. Todetermineh ow ad rugc andidatei s metabolised, humanl ivers lices,h umanl iverhepatocytesand humanl iverm icrosomescanbe used inconjunction with inhibitors ofspecific P450forms anda ntibodiest os pecific P450s.
14 Recombinant humanP450s,e xpressed ins ystems such asbaculovirus,h avea lso gained widespread use. 15, 16 Inp ractice,b othh umanl iver-derived cells ande xtracts and recombinant P450s areused to determinehow acompoundis metabolised.High-throughput robotic screeningprocedures haveb eendeveloped usingrecombinant P450s ino rdert o predicthow drugc andidatesw ill be metabolised inhumans. Todeterminewhich P450hast he highest rateofmetabolism for aparticularcompound, standardM ichaelis-Menton kineticsareused to estimatethe relativerateofc learance or Km/Vmax. Inaddition,itshouldalso be noted thatcomputer modellingh asbeeno fsomevaluei np redictingmetabolism withc ertainhumanP450s,such asCYP2C9andC YP2D6.
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Humanised mice
Two strategiescanbe used to produce ahumanised mouse. Historically,placingthe cDNA behindatissue-specific promoterhasbeenused to maketransgenic mice bystandard pronuclei injection ofrecombinant DNA.For example, the rat albuminorm ousetransthyretinpromotercanbe used to make transgenic micethatw ouldallowfor tissue-specific expression inliver. Asanexample, the humanfoetal CYP3A7 was expressed inliverusingametallothionein-1promoter.
18
Asecondstrategyfor
The BACclonecontainingthe full geneshouldnot contain othergeneopenreadingframes. Severaltransgenic founders (independent offspringderived fromthe egg injections) shouldbecharacterised to findalinethatexhibits expression ofthe transgeneinatissue-specific mannerthatreflects the expression foundinhumans. Inthe experience ofthe author, BACtransgenesarestableandexpressed overmany generations.
CYP2D6-humanised mice
Mice containn ine Cyp2D genes; however,noneofthese genesappeart oencode P450s withc atalytic activitiess imilar to CYP2D6,the only CYP2D geneproductexpressed in humans. 12, 19 Int he absence ofthisactivity,h umanised mice canbe developed byinsertion ofthe CYP2D6 genei nto the wild-typemouseg enome.A CYP2D6 -humanised mouse wasproduced usingalambda phage genomic clonecontaining the wild-type CYP2D6 gene. 20 Interestingly,severalfounder linesw ereproduced, all expressingC YP2D6p roteininl iver. Ac oupleoftheselinesalso expressed the enzymei nkidney, however,a ndonee xpressed CYP2D6int he liver,k idneyand small intestine-known siteso fe xpression ofthisP450in humans. 21 Thisl atterl inewasu sed to determinethe activity ofC YP2D6t owardd ebrisoquine, anantihypertensiveb etaadrenoceptor blockingd rugthatism etabolised byCYP2D6 primarily through 4-hydroxylation.Thisr eaction hasbeen used for many years asan inv ivo and inv itro metabolic probe for CYP2D6,since the discovery in1 977 ofthe CYP2D6 polymorphism. 22 The humanised micewereableto efficiently metabolised ebrisoquine, withpharmacokinetic parameters andurinary metabolitelevels reflectiveofh umanextensive metabolisers ofd ebrisoquine. 21 Toanalysethe metabolism ofd ebrisoquine inv ivo,pharmacokinetic (PK)analysisw as carried out. Mice area dministered debrisoquineb yo ral gavage andbloodsamplestakenatv arious timesandsubjected to analysisbyl iquid chromatography-mass spectrometry/mass spectrometry. Thesestudiesr evealed thatm ice havingtwo copieso fthe transgenec lusterhad alowarea undert he curve(AUC)for debrisoquinea ndahigh AUCf or 4-hydroxydebrisoquine, whilewild-typemice produced littleof the metabolitea ndh ad ahigh AUCf or the parent compound (Figure2). Mice hemizygous for the transgenec lusterw ere intermediateb etweenw ild-typea ndh omozygote.
Asecondmeasureofdebrisoquinemetabolism invivo is determination ofthe metabolic ratio(MR)ofdebrisoquine/ 4-hydroxydebrisoquineinthe urine, the standardmethodfor analysingdebrisoquinemetabolism inhumans. Thisanalysis revealed thatthe MR inwild-typemice wasaround10 and thatofCYP2D6-humanised mice,bothhomozygous and hemizygous,wasabout1;the latterv alueissimilartothat foundinhumanextensivemetabolisers.Thesestudiesconfirm thatwild-typemice aresimilartohumanpoormetabolisers of debrisoquine, andthatCYP2D6-humanised micearesimilar to extensivemetabolisers.Thesestudiesestablishthe feasibility of usinghumangenomic clonesfor the production ofP450-humanised micethatexhibit invivo metabolic activity thatis similartohumans. Humanised micehavealsobeenused to determinethe mechanism oftissue-specific expression of CYP2D6. The CYP2D6 transgenewasbred into aliver-specific null mousefor hepatocyte-enriched nuclearfactor4alpha (HNF4alpha). 23 Mice lackingexpression ofHNF4alpha inthe liverhavemarkedly decreased expression ofthe CYP2D6 transgene, indicatingarolefor thisfactorinthe control ofthe liver-specific expression ofCYP2D6(Figure3). Expression is not lostinthe absence ofHNF4alpha, however,indicatingthat otherliver-enriched factorsmayhavearoleinits expression.
CYP2D6m etabolisesalarge numbero fd rugst hatare used int he treatment ofpsychiatric disorders,i ncludingthe antidepressants amitriptyline, fluoxetinea ndi mipramine, and the neuroleptic agents haloperidol andrisperidone.In addition,C YP2D6carrieso ut the demethylation ofc odeine to the morepotent analgesic morphine.Thesed atasuggested thatendogenous neurochemicals ubstratesm ayexist for CYP2D6. Molecularm odellingh asbeenu sed to analyse CYP2D6s ubstrates. Thisr evealed that5-methoxytryptamine (5-MT)isapotentials ubstratef or thisP450. Indeed, 5-MT wasfoundto be demethylated to 5-hydroxytryptamine (5-HT),a lso called serotonin,b yr ecombinant CYP2D6and transgenic CYP2D6.
24 Conversion of5 -MT to 5-HT occurs
Figure2. The pharmacokineticso fd ebrisoquineinCYP2D6-humanised mice.Timec ourseofserum concentrations of(A)debrisoquine(DEB)and(B)4-hydroxydebrisoquine(4-OH-DEB)fromwild-type, CYP2D6-humanised heterozygous andC YP2D6-humanised homozygous mice afteronesingleoraladministration ofDEB (2.5mg/kg). Venous bloodwaso btained 0,0.5, 1,2,4,6,8,12 and24 hours afterDEB administration. Valuesrepresent the meanandthe verticall inesthe standarderrors ofthe meano fDEB and4 -OH-DEB fromt hree mice.
atahigherr atei nt he CYP2D6-humanised miceascompared withthe wild-typemice.Thesestudiesrevealed anewrolefor CYP2D6int he serotonin-melatonincycle.
CYP3A4-humanised mice
CYP3A4 ist he mostimportant ofthe humanP450s for the metabolism ofd rugs. Itist he most abundantly expressed P450inhumanl iverm icrosomesandi sknown to metabolise morethan6 0p ercent ofa ll therapeutic drugsu sed int he treatment ofmany disorders,i ncludingh ypercholesterolaemia (statindrugs),b acterialinfections( erythromycin) and autoimmunity (cyclosporine). Thus,the potentialfor drug interactions isgreatandi so fc oncern for the development of newdrugs. 25 Inhumans,f our CYP3AP 450s aree xpressed: CYP3A4,C YP3A5,C YP3A7andC YP3A43. Interestingly, mice havee ight CYP3A genes. 12 The mostabundantly expressed CYP3A genei nhumans is CYP3A4.ThisP450is especially ofi nterest becausei tisn ot only expressed inl iver, but also int he gut,wherei tcanm etabolisealarge numberof orally administered drugs. Togeneratemice thatexpress humanCYP3A4, aBAC was used asatransgene. 26 Thesemicee xpressed high levels of CYP3A4 proteinint he small intestine.Surprisingly,little expression wasfoundi nt he liver,amajor siteofC YP3A4 expression inhumans; however,recent studieshaverevealed constitutivea ndi nduciblee xpression int he livers off emale mice (Yu etal .,unpublished results) . ToevaluateC YP3A4 catalytic activity,the drugmidazolamw asu sed, since itisa standardprobe for CYP3A4 activity inhumans. 27 Midazolam iso xidised att he 4a nd1 0 positionsbyCYP3A4.The pharmacokineticso fmidazolamm etabolism wered etermined upon oraladministration ofthe drug.DifferencesinAUCf or the parentalcompoundandthe primary 1 0 -hydroxymidazolam wered etected betweent he CYP3A4-humanised andwildtypemice,i ndicatingthatt he trangenicshaveahigherr ateof midazolamm etabolism andc learance (Figure4 ). Nodifferencesw ereobserved betweent he transgenic micea ndwildtypemicewhent he drugwasadministered intravenously. Thesemice will aid int he inv ivo analysiso forally administered drugst hataresubstratesfor CYP3A4.Theyw ill also be ofvaluei ndeterminingthe mechanism oftissue-specific and inducibleregulation ofthe CYP3A4 gene.
Conclusions
Xenobiotic-metabolisingenzymesarethe interface between humans andtheirchemicalenvironment.Whiletheyare absolutely required for the elimination ofclinically used drugs, theycanlead to adversedrugeffects dueto druginteractions andpolymorphisms. Theseenzymesarealso responsiblefor the activity ofchemicalcarcinogens. Thus,drugsandchemicals to be used inhumans must carefully be tested to determinehow theywill be metabolised.While invitro systems havebeen developed to predicthumanmetabolism ofdrugs,analysisof drugmetabolism invivo,usingrodents,canleadto uncertainty dueto speciesdifferencesinxenobiotic-metabolisingenzymes. Humanised miceexpressinghumanP450s canbe used to fill the gapbetween invitro and invivo testingsystems. The CYP2D6-andCYP3A4-humanised mousemodels validatethe production anduseofthesenewmodels for the studyof invivo pharmacogenetics. The challenge remains,however,to produce fully humanised miceinwhich the endogenous mousegenesare knocked out. Whiletargeted genedisruption hasbeenused to knock out the CYP1 family and CYP2E1 ,most ofthe CYP2 subfamiliesinmice consist ofmultiplegenes. For example, the CYP2 and CYP3A loci inmiceconsist ofnineandeightgenes, respectively,spanninghundredsofkilobasesofDNA.Thus, standardgeneknockout technologycannot be used to delete the wholesubfamily.Whileeach genecanbe disrupted,
The figureshows aN orthern blot analysiso fmouseliver HNF4alpha expression. Hepatic RNAs( 10 mcg)from HNF4alpha wild-type:CYP2D6 þ / 2 (lanes1,2); HNF4alpha liver-null: CYP2D6 þ / 2 (lanes3 ,4); HNF4alpha wild-type:-CYP2D6 2 / 2 (lanes5, 6); andHNF4alpha liver-null: CYP2D6 2 / 2 (lanes7,8)w ereseparated on a1p ercent agarosegel, transferred to anylon membranea ndh ybridised withan HNF4alpha exons 4a nd5cDNA probe.HNF4alpha was completely deleted afterCre-mediated recombination. Betaactinw asu sed asaloadingc ontrol. Western blot analysiso f CYP2D6p roteinexpression inlivermicrosomalp rotein (40m cg)derived fromt he samegroups ofmice ast hoseused for RNA analysis. Deletion ofH NF4alpha resulted inaloss of morethan50percent ofCYP2D6p roteinexpression. The blots werere-probed withanantibodyt oCYP2E1inordert o verifyloadinga ndthe presence ofmicrosomalp roteins inall the samples.
the modified genescanneverbe joined on asinglechromosome dueto theirproximities. Nevertheless,the Cre-loxPstrategyisa methodthatcanallowalarge segment ofDNA containing the wholeP450subfamily to be deleted. 28 LoxPsitesareinserted ateach endofthe P450locus byconsecutivetransfection of recombinant DNAsinto embryonic stem(ES)cells usingstandardprotocols (Figure5). 29 The interveningsegment ofDNA canbe deleted inES cells usingtransfected Crerecombinase. Alternatively,deletion canbe carried out inthe mouseembryo or adult mouseusingaCrerecombinasetransgene.Byuseofthis method, all ofthe non-essentialxenobiotic-metabolisingP450s canbe deleted andreplaced withtheirhumancounterparts, leadingto afully P450-humanised mouse.
q United StatesFederalGovernment Figure5. Useofthe Cre-loxPstrategyt odeletea nentire subfamily ofP450genes. The individualgenesaredenoted by rectanglesandthe loxPsitesbytriangles. The sequence ofthe locus canbe obtained fromt he public or Celerad atabase, and bacterialartificialchromosomec lonest hatflankthe complete clusterofg enescanbe chosen. LoxPsitesarei ntroduced by useof invivo recombination to generatec onstructs for transfection into embryonic stem(ES)cells. 29 Thisiscarried out byt wo consecutivetransfections into ES cells followed by treatment withCrerecombinaseto deletethe DNA between the loxPsites. The ES cells canthenbe used to makea knockout mouse.
